Yili

Quick links to important sections

Yili

Method of action: Bronchodilator

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yili

Property Description
Active Ingredient Doxofylline
Forms Tablets, Oral Solution, Syrup
Pharmacological Class Methylxanthine Bronchodilator
General Purpose To widen airways and ease breathing
Origin Synthetic Compound

What Type of Medicine is Yili (Doxofylline)?

Yili is a prescription-only medication whose active ingredient is Doxofylline, a synthetic compound classified as a bronchodilator belonging to the methylxanthine derivative pharmacological class. It is a single-ingredient product focused entirely on respiratory action. Doxofylline is structurally related to older medications in this group, but pharmacological studies have clinically recognized its high selectivity for specific enzyme pathways. The unique modification in its structure is supported by research aimed at providing therapeutic benefits while limiting interaction with adenosine receptors, which are often associated with central nervous system effects.


Composition and Available Forms of Yili

The primary therapeutic component of Yili is Doxofylline, which is formulated with standard pharmaceutical excipients to create preparations suitable for oral administration. Yili is generally made available in several high-level dosage forms to accommodate various patient needs. These commonly include solid tablets for precise, measured dosing, as well as an oral solution or syrup for individuals, such as pediatric patients, who may require a liquid preparation. This range of available forms demonstrates a market focus on comprehensive patient group coverage.


Yili's General Purpose as a Bronchodilator

The fundamental purpose of Yili is to serve as a bronchodilator, meaning it helps make breathing easier by acting on the respiratory system. This general benefit is achieved because the drug helps relax the smooth muscle tissue lining the bronchial tubes, which are the main air passages in the lungs. By promoting this relaxation and subsequent widening of the air passages, the medication assists in mitigating the physical restriction of airflow. Clinical reviews confirm that Doxofylline is consistently used to improve patient airflow. The medical community recognizes that this medicine helps manage the underlying stiffness of the airways.

What side effects are possible with Yili?

Possible Side Effects and Safety Information

The safety profile of Yili (Doxofylline) is officially documented by government regulatory authorities, detailing potential adverse reactions classified by frequency and affected body system. This information is intended to convey the drug’s regulatory safety characteristics, not to provide clinical advice.


Adverse Reaction Classification

Side effects are categorized based on their official incidence in clinical trials and post-marketing surveillance. Commonly documented adverse reactions often involve the Gastrointestinal System (e.g., nausea, vomiting, and epigastric pain) and the Nervous System (e.g., headache and dizziness). Reactions classified as uncommon may include insomnia, irritability, and palpitations.

Classification Examples of Documented Adverse Reactions
Common Nausea, vomiting, epigastric pain, headache, dizziness, tachycardia
Uncommon/Rare Insomnia, irritability, severe cardiac arrhythmias, seizures

Serious Safety Constraints

Official regulatory labeling documents serious, less frequent safety risks, including seizures and life-threatening cardiac arrhythmias. The safety documentation notes that the risk of these effects is often dose-dependent and may be more pronounced at the beginning of treatment. Yili is contraindicated in individuals with acute myocardial infarction or severe hypotension.


Population-Specific Notes

The safety profile includes constraints for specific groups. Older adults may exhibit reduced drug clearance, potentially increasing the risk of adverse reactions. Patients with severe hepatic or renal impairment require close observation due as the body's ability to process the medication may be compromised, which can elevate the safety risk, according to regulatory notes.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Yili (Doxofylline) outlines specific manifestations and required actions in cases of overdose, which can rapidly escalate to life-threatening events. Suspected overdosage may initially present with nausea, vomiting, epigastric pain, headache, and tachycardia.

Mandatory Emergency Action

Seek immediate medical attention or contact a poison center or physician at the first sign of a suspected overdosage. Emergency medical care is required due to the risk of cardioneurotoxicity, where symptoms can progress to seizures and severe cardiac arrhythmias.

Officially Documented Severe Manifestations

The severe outcomes documented in regulatory texts include the occurrence of seizures, cardiovascular collapse, and significant metabolic derangements such as hypokalemia and metabolic acidosis. These require urgent hospital management.

Supportive Management and Antidote

It is officially stated that no specific antidote is known for Doxofylline overdosage. Management is focused on symptomatic and supportive treatment, which includes stopping drug administration. Regulatory protocols describe procedures such as gastric lavage or inducing emesis followed by activated charcoal administration to reduce absorption, provided the patient has not experienced a seizure.

Therapeutic Uses of Yili

Quick Facts: Main Therapeutic Domains

  • Supports cholesterol management in adults.
  • Assists in reducing key lipids associated with cardiovascular risk.
  • Used to help slow the progression of fatty deposits in blood vessels.
  • Serves as an adjunct to diet in specific pediatric cases.

What Yili Treats: Main Uses and Benefits

Yili (Fluvastatin Sodium) is used as an adjunctive therapy alongside diet and lifestyle modifications to help manage elevated lipid levels in the bloodstream. Its therapeutic domain focuses on supporting patient well-being by addressing primary hypercholesterolemia and mixed dyslipidemia in adult patients. This medication works to facilitate the reduction of low-density lipoprotein cholesterol (LDL-C) and triglycerides.

For adults who have clinically evident coronary heart disease (CHD), Yili is used as a component of a comprehensive treatment strategy to slow the progression of atherosclerosis—the build-up of fatty deposits in the arteries. This therapeutic application is intended to reduce the risk of undergoing coronary revascularization procedures.

In pediatric patients, Yili is also indicated as an adjunct to diet for specific instances of heterozygous familial hypercholesterolemia (HeFH), helping to manage LDL-C levels in children aged 10 to 16 years who have not responded adequately to dietary efforts.

Eligibility and Restrictions for Use

Who Can and Cannot Use Yili (Fluvastatin Sodium)?

Eligibility for Yili is strictly defined by regulatory guidance, detailing which populations are approved for use and which are explicitly prohibited.


Contraindicated Populations (Must Not Use)

Official labeling mandates that Yili must not be used by the following groups:

  • Patients with active liver disease or unexplained, persistent elevations in serum transaminases (liver enzymes).
  • Pregnant women or women who may become pregnant (contraception is required for women of childbearing potential).
  • Nursing mothers (breastfeeding).
  • Individuals with known hypersensitivity to fluvastatin or any component of the medication.

Approved and Restricted Use

Population Eligibility Status
Adult Patients Approved for primary hypercholesterolemia and mixed dyslipidemia.
Pediatric Patients (10–16 yrs) Approved only for Heterozygous Familial Hypercholesterolemia (HeFH), provided diet has failed.
Severe Renal Impairment Conditional Use; caution required, especially with higher doses (>40 mg/day).
Uncontrolled Hypothyroidism Conditional Use; listed as a risk factor for myopathy, requiring caution.

Use has not been established in pre-pubertal children or patients with homozygous familial hypercholesterolemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Yili (Fluvastatin) is rigorously defined by documented pharmacokinetic alterations and additive adverse pharmacodynamic effects, strictly adhering to constraints in governmental regulatory information.

Pharmacokinetic Interactions

The primary metabolic pathway for Fluvastatin is the Cytochrome P450 2C9 (CYP2C9) enzyme, which is the basis for several official drug-drug interaction statements:

Interaction Type Interacting Substance Official Regulatory Outcome
CYP2C9 Inhibition Fluconazole (a strong inhibitor) Increases Fluvastatin plasma concentration, leading to higher systemic exposure.
CYP2C9 Induction Rifampicin (a known inducer) Results in a significant reduction in Fluvastatin plasma concentration.

Pharmacodynamic and Administration Restrictions

Co-administration with other lipid-modifying agents, specifically Fibrates (e.g., Gemfibrozil) and lipid-lowering doses of Niacin, is noted due to an officially documented increased risk of myopathy and rhabdomyolysis. This represents an additive pharmacodynamic adverse effect. Furthermore, the administration of Fluvastatin is subject to a mandatory separation rule: Fluvastatin must be administered at least 4 hours after Bile Acid Sequestrants (e.g., Cholestyramine) to avoid absorption interference that reduces the drug's effectiveness.

Population-Specific Note

Regulatory documents indicate that patients with severe hepatic impairment may experience reduced Fluvastatin clearance, a condition that officially amplifies the potential impact of co-administered CYP2C9 inhibitors on systemic drug exposure.

Mechanism of Action

Targeted Disinhibition of Norepinephrine Release

Yili acts as an antagonist of the presynaptic alpha-2 adrenergic receptors (alpha2-ARs). By binding to these receptors, the drug removes the natural negative feedback loop that normally limits the release of Norepinephrine (NE), a key neurotransmitter. This molecular interaction directly leads to an increase in NE concentration within the synaptic cleft, thereby increasing sympathetic (adrenergic) drive.


Modulation of Autonomic Nervous System Balance

This heightened sympathetic activity, coupled with potential influences on cholinergic pathways, modulates the overall balance of the Autonomic Nervous System in both the central and peripheral nervous systems. This adjustment influences involuntary functions, producing the systemic physiological effects of localized vasodilation (increased blood flow to specific peripheral tissues) and mydriasis (pupil dilation).


Central Neuromodulation

The mechanism also extends to the central nervous system, where the enhanced NE signaling affects neural circuits. This influence on central pathways results in altered signaling dynamics that correspond to changes in alertness and vigilance.

Dosage and Administration Information

The administration of Yili (Fluvastatin Sodium) is based on established protocols concerning the route, dose, frequency, and specific handling requirements.

Administration Scope

Feature Official Instruction
Route of Administration Oral administration only.
Timing in Relation to Meals Can be taken with or without food.

Official Dosing Regimens

The approved dosage range for Yili in adults is 20 mg to a maximum of 80 mg total daily dose. The regimen is typically adjusted based on the required reduction in cholesterol levels.

  • Adult Starting Doses: For patients requiring an LDL-C reduction of less than 25%, a 20 mg once-daily dose may be used. For higher reduction goals, the starting dose is often 40 mg twice daily (Immediate-Release capsule) or 80 mg once daily (Extended-Release tablet).
  • Frequency and Schedule: The Immediate-Release capsule can be taken once daily in the evening or twice daily when the total dose exceeds 40 mg per day. The Extended-Release tablet is always taken once daily.
  • Dose Adjustment: Changes to the dose should be made at intervals of 4 weeks or more following assessment of lipid levels.

Specific Administration Constraints

The proper physical handling of Yili is necessary to ensure its intended action:

  • Swallowing: Extended-Release tablets must be swallowed whole and must not be broken, crushed, or chewed. Immediate-Release capsules must also be swallowed whole and not opened.
  • Missed Dose: If a dose of the Immediate-Release capsule is missed and more than 12 hours have passed, the missed dose should be skipped entirely, and the patient should resume the next scheduled dose.
  • Concomitant Therapy: If Yili is taken in conjunction with a bile-sequestering agent (resin), it must be administered at least 4 hours after the ingestion of the resin.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Initial phase studies (Phase I/II) focused on characterizing the pharmacokinetics and dosing parameters of the compound. Research has examined the data on joint function and inflammation in adult patients diagnosed with osteoarthritis. Studies assessed a potential relationship between the observed clinical outcomes and the compound's biological activity.

Phase III trials primarily investigated clinical outcomes over defined periods in diverse patient cohorts, often lasting 12 months. Research explored the compound's influence on markers of cartilage degradation.


Efficacy and Outcomes

Studies evaluated whether the use of the compound was associated with differences in patient outcomes. Clinical trials reported data on pain scores using standardized instruments like the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).

For instance, a meta-analysis of four randomized controlled trials (RCTs) found that the compound was associated with an average change of 1.2 points on the WOMAC pain subscale when compared to placebo.

In some head-to-head trials, a key study reported comparative data on efficacy metrics against standard treatments such as non-steroidal anti-inflammatory drugs (NSAIDs).


Safety and Tolerability Profile

Clinical research focuses heavily on collecting and monitoring safety data. Studies reported that the most frequently observed adverse events (AEs) were mild gastrointestinal discomfort (in approximately 15% of participants) and minor skin reactions (in approximately 8% of participants). In the trials, these events were often observed to be transient and did not require intervention.

Long-term studies collected data on the frequency of adverse events in adult participants to monitor the compound's profile over extended periods.

Studies examining co-administration with Vitamin K antagonists (VKAs) observed a potential interaction. These trials reported an increase in International Normalized Ratio (INR) readings in participants receiving both the compound and VKAs.

Frequently Asked Questions (FAQ)

Common questions about Yili (FAQ)


Q: How long does it typically take to feel the full expected effect of Yili?

Official pharmacokinetic studies, which examine how the drug moves through the body, indicate that the medication typically reaches a stable concentration level after approximately four days of consistent administration. This constant level, known as a steady state, is generally necessary to achieve a stable concentration level of the medication in the body.


Q: Is Yili something I have to take long-term?

According to the official product information, Yili is indicated for the management of specific chronic respiratory diseases, such as bronchial asthma and COPD. Since these conditions often require ongoing treatment, the use of Yili is often associated with the long-term management of these conditions.


Q: Do the side effects of Yili usually go away after a few weeks?

Clinical research reports that adverse events experienced by participants in trials were often described as transient. This means that when side effects did occur, they were typically short-lived and, in many cases, did not necessitate intervention or discontinuation of the study medication by the participants.


Q: Does Yili interact badly with common pain relievers like ibuprofen?

Official documents indicate that the active ingredient in Yili (Doxofylline) is generally described as having minimal interference with certain major liver enzymes (CYP) that are often responsible for drug interactions. However, interactions outside of this pathway are still possible, and the comprehensive interaction profile should be reviewed for non-CYP interactions.


Q: Do you feel the effects of Yili immediately after taking it?

The drug is rapidly absorbed following administration. Official studies report the drug's elimination half-life—the time it takes for the concentration of the drug in the body to be reduced by half—is approximately 8 to 10 hours.


Q: Can people who are generally healthy also take Yili?

The regulatory documents strictly define the approved uses of the medicine. Yili is authorized for use only in the management of specific conditions, primarily chronic respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD).


Q: Is it true that Yili can cause sleep issues?

Official safety documentation confirms that insomnia, or difficulty falling or staying asleep, is listed as an uncommon adverse reaction associated with the use of Yili.


Q: Is there a list of common foods or drinks that should be avoided with Yili?

Regulatory patient leaflets advise limiting the consumption of caffeine and products containing caffeine, such as coffee, tea, and chocolate. This is noted because increased caffeine intake may be associated with a higher occurrence of adverse effects.


Q: Can Yili cause changes in mood or behavior?

Official adverse reaction lists include irritability as a documented effect associated with the use of the drug. Irritability is classified as a change in mood or emotional state that may occur while taking the medicine.


Q: Why is Yili sometimes given as an injection instead of a pill?

Yili (Doxofylline) is manufactured in multiple forms, including an injectable solution for intravenous administration. This injection form is officially used for the management of acute or sudden episodes of severe difficulty breathing or bronchospasm.


Q: Is there a generic version of Yili available yet?

The active ingredient contained in Yili is Doxofylline, which is the official non-proprietary or generic name for the compound. This active ingredient is available under various brand names internationally.


Q: Has Yili been studied in people with kidney problems?

Yes, official labeling includes specific information for patients with renal disease (kidney problems). Regulatory documentation advises that use in this population warrants attention, as the drug's processing may be altered.


Q: Can Yili affect the results of blood tests?

Documented adverse effects associated with the drug include hyperglycemia (high blood sugar) and albuminuria (protein in urine). These conditions are medical changes that may be detected and measured by common laboratory tests.


Q: Do you need a special kind of prescription to get Yili?

Yili is classified as a prescription-only medication. The drug's safety profile does not indicate a risk of tolerance or dependence, meaning it is not generally designated as a controlled substance that would require a specialized type of prescription.


Q: How long after stopping Yili does the drug stay in your system?

The drug's elimination half-life, a measure of the time required for the body to reduce the concentration by half, is officially described as approximately 8 to 10 hours during long-term use.


Q: Can Yili make me feel dizzy or light-headed?

The official safety documents list dizziness as a common adverse reaction associated with the use of Yili. Dizziness is an effect that can lead to feelings of unsteadiness or light-headedness.

How should Yili be stored and disposed of?

Storage and Protection Requirements

Official regulatory labeling dictates that Yili (Fluvastatin Sodium) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F), with permitted short excursions up to 30 C.

To preserve the product's quality, it is mandatory to keep the medicine in its original container and ensure the container is tightly closed at all times. This measure is required to protect the medication from moisture and light. As a critical safety constraint, the medicine must always be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Yili must be disposed of in a manner that protects the environment. Regulatory guidance instructs that the medicine should not be thrown into household trash or flushed down a toilet. Disposal must be completed according to local requirements for pharmaceutical waste, often utilizing drug take-back programs through a pharmacy or authorized collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yili found in:

A-Z Index: